Bellerophon Therapeutics (NASDAQ:BLPH) posted its quarterly earnings results on Wednesday. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.30, MarketWatch Earnings reports.
Shares of BLPH traded up $0.13 during trading hours on Thursday, hitting $1.10. The company had a trading volume of 943,924 shares, compared to its average volume of 469,052. The firm has a market cap of $51.74 million, a PE ratio of -1.22 and a beta of -0.21. Bellerophon Therapeutics has a 52-week low of $0.47 and a 52-week high of $3.30.
BLPH has been the subject of several recent analyst reports. Zacks Investment Research lowered Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 11th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Bellerophon Therapeutics in a research report on Thursday, August 2nd.
TRADEMARK VIOLATION NOTICE: “Bellerophon Therapeutics (BLPH) Releases Quarterly Earnings Results, Beats Estimates By $0.30 EPS” was first reported by WKRB News and is the sole property of of WKRB News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.wkrb13.com/2018/11/09/bellerophon-therapeutics-blph-releases-quarterly-earnings-results-beats-estimates-by-0-30-eps.html.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
See Also: What does earnings per share mean?
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.